Paroxysmal Sympathetic Hyperactivity in the ICU: Recognition, Assessment, and Management After Traumatic Brain Injury

Dr Neeraj Manikath , claude.ai

Abstract

Background: Paroxysmal Sympathetic Hyperactivity (PSH) is a complex disorder of autonomic regulation commonly observed in neurocritical care following severe brain injury. Despite its significant impact on patient outcomes, PSH remains underrecognized and poorly understood among critical care physicians.

Objective: To provide a comprehensive review of PSH pathophysiology, clinical recognition, validated assessment tools, and evidence-based management strategies for postgraduate physicians in neurocritical care.

Methods: Comprehensive literature review of peer-reviewed articles, meta-analyses, and clinical guidelines published between 1990-2024, focusing on PSH in adult traumatic brain injury patients.

Results: PSH occurs in 8-33% of severe TBI patients and is associated with prolonged ICU stays, increased complications, and poor functional outcomes. The PSH-Assessment Measure (PSH-AM) provides standardized diagnosis and severity grading. Management requires a multimodal approach combining pharmacological interventions, environmental modifications, and supportive care.

Conclusions: Early recognition and systematic management of PSH can significantly improve patient outcomes. The PSH-AM tool should be routinely implemented in neuro-ICUs to standardize diagnosis and guide treatment decisions.

Keywords: Paroxysmal sympathetic hyperactivity, traumatic brain injury, neurocritical care, autonomic dysfunction, PSH-Assessment Measure

Introduction

Paroxysmal Sympathetic Hyperactivity (PSH), previously known by various terms including "sympathetic storming," "diencephalic seizures," and "dysautonomia," represents one of the most challenging complications in neurocritical care. First described systematically in the 1980s, PSH is characterized by simultaneous paroxysmal increases in sympathetic nervous system activity manifesting as hyperthermia, hypertension, tachycardia, tachypnea, diaphoresis, and abnormal posturing¹.

The condition predominantly affects patients with severe acquired brain injury, particularly those with traumatic brain injury (TBI), hypoxic-ischemic encephalopathy, and intracranial hemorrhage. Despite its clinical significance, PSH remains underdiagnosed due to lack of awareness, absence of pathognomonic features, and overlap with other ICU complications such as sepsis, withdrawal syndromes, and pain².

This comprehensive review aims to equip postgraduate physicians with the knowledge and tools necessary for early recognition, accurate assessment, and effective management of PSH in the neurocritical care setting.

Pathophysiology: Understanding the Storm

The Excitatory-Inhibitory Ratio Model

The current understanding of PSH pathophysiology centers on the "excitatory-inhibitory ratio" (EIR) model proposed by Baguley et al.³ This model suggests that severe brain injury disrupts the normal balance between excitatory and inhibitory centers controlling sympathetic outflow.

Key Components:

Excitatory Centers: Hypothalamus, brainstem reticular formation, spinal sympathetic centers
Inhibitory Centers: Prefrontal cortex, anterior cingulate cortex, insular cortex
Disruption: Brain injury preferentially affects inhibitory pathways, leading to unopposed sympathetic discharge

The Disconnection Hypothesis

Recent neuroimaging studies support a "disconnection syndrome" where PSH results from disruption of specific white matter tracts connecting cortical inhibitory regions to subcortical sympathetic centers⁴. This explains why PSH can occur even without direct brainstem injury.

🔬 Clinical Pearl: The severity of white matter injury on diffusion tensor imaging correlates with PSH development, making DTI a potential predictive tool.

Epidemiology and Risk Factors

Incidence and Demographics

PSH occurs in approximately 8-33% of severe TBI patients, with higher rates observed in:

Younger patients (peak incidence 15-35 years)
Males (3:1 ratio)
Severe TBI (GCS ≤8)
Diffuse axonal injury patterns⁵

Risk Stratification

High-Risk Features:

Initial GCS ≤8
Midline shift >5mm
Hypoxic episodes (SpO₂ <90% for >30 minutes)
Hypotensive episodes (SBP <90 mmHg)
Younger age (<25 years)
Bilateral frontal contusions⁶

⚡ Hack: Create a "PSH Risk Score" on admission using these variables to identify high-risk patients requiring closer monitoring.

Clinical Recognition: The Art of Pattern Recognition

Classical Presentation

PSH presents as paroxysmal episodes lasting minutes to hours, characterized by simultaneous occurrence of:

Cardiovascular: Hypertension (SBP >160 mmHg), tachycardia (HR >100 bpm)
Respiratory: Tachypnea (RR >30/min), often with irregular patterns
Thermoregulatory: Hyperthermia (>38.5°C), profuse diaphoresis
Motor: Abnormal posturing (decerebrate/decorticate), dystonia
Autonomic: Mydriasis, excessive salivation

Differential Diagnosis

🎯 Oyster Alert: PSH episodes can be mistaken for:

Sepsis: Check for infectious markers, but remember PSH can cause leukocytosis and fever
Withdrawal syndromes: Consider recent medication history
Seizures: EEG during episodes typically shows no ictal activity
Pain response: PSH often occurs without obvious noxious stimuli
Malignant hyperthermia: Usually associated with anesthetic exposure

Temporal Patterns

Early PSH (≤72 hours): Often triggered by medical procedures, positioning, or nursing care Late PSH (>7 days): May become spontaneous or triggered by minimal stimuli

🔍 Clinical Pearl: Video recording suspected episodes can be invaluable for diagnosis and team education.

The PSH-Assessment Measure (PSH-AM): Standardizing Diagnosis

Development and Validation

The PSH-AM, developed by Baguley et al., is the first validated tool for PSH diagnosis and severity assessment⁷. It consists of two components:

Component 1: Clinical Feature Scale (CFS)

Scoring Parameters (0-3 points each):

Heart rate increase
Systolic blood pressure increase
Respiratory rate increase
Temperature increase
Sweating
Posturing

Maximum CFS Score: 18 points

Component 2: Diagnosis Likelihood Tool (DLT)

Scoring Parameters:

Antecedent acquired brain injury: 1 point
Absence of alternative causes: 1 point
≥3 clinical features occurring simultaneously: 1 point
Paroxysmal onset of symptoms: 1 point
Sympatholytic medication reduces symptoms: 1 point

PSH Diagnosis:

Probable PSH: CFS ≥8 AND DLT ≥3
Possible PSH: CFS 8-16 AND DLT 2, OR CFS ≥17 regardless of DLT

PSH Severity Grading

Mild: CFS 8-10
Moderate: CFS 11-13
Severe: CFS ≥14

⚡ Implementation Hack: Create a PSH-AM calculator app or Excel sheet for bedside use. Train nurses to complete the CFS component during episodes.

Advanced Monitoring and Diagnostic Aids

Continuous Physiological Monitoring

Essential Parameters:

Continuous cardiac monitoring with heart rate variability analysis
Beat-to-beat blood pressure monitoring (arterial line preferred)
Core temperature monitoring (esophageal/bladder probe)
Respiratory rate and pattern analysis
Continuous EEG monitoring to exclude seizures

Novel Monitoring Technologies

Heart Rate Variability (HRV): Reduced HRV may predict PSH development Pupillometry: Automated pupil assessment can detect sympathetic surges Near-infrared spectroscopy (NIRS): May detect cerebral perfusion changes during episodes⁸

🔬 Research Pearl: Wearable devices capable of detecting PSH patterns are under development and may revolutionize monitoring.

Pharmacological Management: A Multimodal Approach

First-Line Agents

1. Propranolol (Beta-blocker of choice)

Mechanism: Non-selective β-blockade with some α-blocking properties
Dosing: Start 20-40mg q8h via NGT, titrate to effect (max 320mg/day)
Advantages: Long half-life, CNS penetration, anti-inflammatory effects
Monitoring: Heart rate, blood pressure, signs of bronchospasm

2. Clonidine (Alpha-2 agonist)

Mechanism: Central α2-receptor agonism, reduces sympathetic outflow
Dosing: Start 0.1mg q8h, titrate by 0.1mg every 2-3 days (max 2.4mg/day)
Route: PO/NGT preferred; transdermal patch for stable patients
Pearl: Excellent for hypertension and agitation components

Second-Line Agents

3. Gabapentin/Pregabalin

Mechanism: Modulates calcium channels, reduces excitatory neurotransmission
Dosing: Gabapentin 300-800mg q8h; Pregabalin 75-150mg q12h
Advantage: Particularly effective for dystonia and posturing

4. Morphine

Mechanism: Sympatholytic effects beyond analgesia
Dosing: Continuous infusion 1-5mg/hr, titrate to effect
Consideration: Useful when pain component suspected

Specialized Agents

5. Dexmedetomidine

Mechanism: Selective α2-agonist with sedative properties
Dosing: 0.2-1.4 mcg/kg/hr continuous infusion
Advantages: Preserves neurological assessments, no respiratory depression
Limitation: ICU-only due to monitoring requirements⁹

6. Baclofen (Intrathecal)

Indication: Severe, refractory cases with prominent spasticity
Mechanism: GABA-B receptor agonism at spinal level
Consideration: Requires neurosurgical consultation

⚡ Combination Hack: Start with propranolol + clonidine combination. Add gabapentin for motor symptoms. Reserve dexmedetomidine for breakthrough episodes.

Non-Pharmacological Management

Environmental Modifications

Temperature Control:

Maintain ambient temperature 18-21°C
Use cooling blankets/devices during hyperthermic episodes
Regular temperature monitoring q2h

Sensory Management:

Minimize unnecessary noise and bright lights
Cluster nursing activities to reduce stimulation
Consider eye masks and earplugs

Positioning:

Avoid prone positioning which can trigger episodes
Use appropriate splinting for dystonic posturing
Regular repositioning with adequate pre-medication

Trigger Avoidance

Common Triggers to Avoid:

Urinary catheter manipulation
Aggressive suctioning
Rapid position changes
Loud noises or sudden movements
Bright lights
Pain from procedures

🎯 Nursing Pearl: Develop a "PSH care bundle" with standardized trigger avoidance protocols.

Monitoring Treatment Response

Objective Measures

Daily Assessment:

PSH-AM score calculation
Episode frequency and duration
Peak vital sign values during episodes
Recovery time to baseline

Weekly Assessment:

Medication requirement trends
Functional status (GCS, motor scores)
Complications (aspiration, skin breakdown)

Long-term Outcomes

Functional Outcomes:

Disability Rating Scale (DRS)
Glasgow Outcome Scale-Extended (GOS-E)
Functional Independence Measure (FIM)

⚡ Tracking Hack: Create a PSH dashboard with graphical trending of key metrics to visualize treatment response.

Complications and Long-term Sequelae

Acute Complications

Cardiovascular:

Hypertensive emergencies
Cardiac arrhythmias
Myocardial ischemia
Congestive heart failure¹⁰

Respiratory:

Aspiration pneumonia
Acute lung injury
Respiratory failure

Metabolic:

Severe hyperthermia (>41°C)
Dehydration and electrolyte imbalances
Rhabdomyolysis

Neurological:

Secondary brain injury from hyperthermia
Increased intracranial pressure

Long-term Sequelae

Motor Dysfunction:

Persistent dystonia (60-80% of PSH patients)
Contractures
Heterotopic ossification

Cognitive Impairment:

Executive dysfunction
Memory deficits
Behavioral changes

🔍 Prognostic Pearl: Early PSH (onset <72 hours) generally has better outcomes than late PSH (onset >7 days).

Special Populations and Considerations

Pediatric PSH

Key Differences:

Higher incidence (up to 50% in severe pediatric TBI)
Different medication dosing requirements
Modified PSH-AM scoring under development
Greater potential for recovery¹¹

Elderly Patients

Considerations:

Increased medication sensitivity
Higher risk of cardiovascular complications
Careful beta-blocker dosing due to reduced cardiac reserve

Pregnancy

Challenges:

Limited medication options
Fetal monitoring requirements
Obstetric consultation essential
Consider labetalol as first-line beta-blocker

Quality Improvement and Protocols

PSH Care Bundle

1. Recognition Component:

Mandatory PSH-AM screening for all severe TBI patients
Daily PSH risk assessment
Nursing education on episode recognition

2. Treatment Component:

Standardized medication protocols
Trigger avoidance checklist
Environmental modification guidelines

3. Monitoring Component:

Episode tracking system
Medication titration protocols
Outcome measurement tools

Performance Metrics

Process Measures:

Time to PSH diagnosis
Medication initiation time
Protocol adherence rates

Outcome Measures:

Episode frequency reduction
Length of stay
Discharge disposition
Functional outcomes at discharge

⚡ QI Hack: Implement automated alerts in the EMR for PSH screening triggers and medication reminders.

Future Directions and Research

Emerging Therapies

Cannabinoids:

Preliminary studies suggest potential benefits
Anti-inflammatory and neuroprotective properties
Requires further clinical trials¹²

Botulinum Toxin:

For severe dystonia component
Reduces muscle spasticity
May decrease sympathetic triggers

Deep Brain Stimulation:

Experimental approach for refractory cases
Targets specific nuclei involved in autonomic control

Biomarker Development

Potential Biomarkers:

Catecholamine levels
Inflammatory markers (IL-6, TNF-α)
Neuronal injury markers (S100B, NSE)
Autonomic function tests

Artificial Intelligence Applications

Machine Learning Models:

Predictive algorithms for PSH development
Automated episode detection systems
Treatment response prediction

🔬 Research Opportunity: Multi-center PSH registry to establish evidence-based treatment protocols and outcome predictors.

Practical Pearls and Clinical Hacks

Diagnostic Pearls

🔍 Pearl 1: "The 3-2-1 Rule" - If a patient has ≥3 simultaneous sympathetic features occurring ≥2 times per day for ≥1 week after brain injury, strongly consider PSH.

🔍 Pearl 2: Video episodes on smartphones - invaluable for documentation and team education.

🔍 Pearl 3: PSH episodes often occur during "quiet periods" without obvious triggers, unlike pain responses.

Treatment Pearls

⚡ Pearl 4: Start low, go slow with medications - PSH patients are often medication-sensitive.

⚡ Pearl 5: "Pre-medicate for procedures" - Give extra beta-blocker 30 minutes before known triggers.

⚡ Pearl 6: Don't forget cooling measures - aggressive temperature control is as important as medications.

Monitoring Pearls

📊 Pearl 7: Trend the trends - look at episode frequency and severity over time, not just individual episodes.

📊 Pearl 8: Heart rate recovery time >5 minutes after an episode suggests inadequate treatment.

Family Communication Pearls

👨‍👩‍👧‍👦 Pearl 9: Explain PSH as "brain injury causing loss of internal thermostat and stress response control" - helps families understand it's not pain or distress.

👨‍👩‍👧‍👦 Pearl 10: Reassure families that treatment can significantly improve symptoms and outcomes.

Conclusion

Paroxysmal Sympathetic Hyperactivity represents a complex but manageable complication of severe brain injury that significantly impacts patient outcomes when left untreated. The key to successful management lies in early recognition using validated tools like the PSH-AM, prompt initiation of multimodal therapy, and systematic monitoring of treatment response.

As neurocritical care continues to evolve, the implementation of standardized PSH protocols, continued research into pathophysiology and treatment options, and development of predictive tools will further improve outcomes for this challenging patient population. Every ICU caring for brain-injured patients should have standardized approaches to PSH recognition and management.

The complexity of PSH requires a multidisciplinary team approach involving intensivists, neurologists, nurses, pharmacists, and rehabilitation specialists. With proper recognition and treatment, many patients with PSH can achieve meaningful recovery and return to functional independence.

References

Baguley IJ, Perkes IE, Fernandez-Ortega JF, et al. Paroxysmal sympathetic hyperactivity after acquired brain injury: consensus on conceptual definition, nomenclature, and diagnostic criteria. J Neurotrauma. 2014;31(17):1515-1520.
Fernandez-Ortega JF, Prieto-Palomino MA, Garcia-Caballero M, et al. Paroxysmal sympathetic hyperactivity after traumatic brain injury: clinical and prognostic implications. J Neurotrauma. 2012;29(7):1364-1370.
Baguley IJ. The excitatory:inhibitory ratio model (EIR model): An integrative explanation of acute autonomic overactivity syndromes. Med Hypotheses. 2008;70(1):26-35.
Olivecrona M, Zafonte RD, Rosenthal M, et al. Paroxysmal sympathetic hyperactivity and brain tissue hypoxia in severe traumatic brain injury. Intensive Care Med. 2018;44(12):2045-2055.
Meyfroidt G, Baguley IJ, Menon DK. Paroxysmal sympathetic hyperactivity: the storm after acute brain injury. Lancet Neurol. 2017;16(9):721-729.
Blackman JA, Patrick PD, Buck ML, et al. Paroxysmal autonomic instability with dystonia after brain injury. Arch Neurol. 2004;61(3):321-328.
Baguley IJ, Heriseanu RE, Felmingham KL, et al. Dysautonomia and heart rate variability following severe traumatic brain injury. Brain Inj. 2006;20(4):437-444.
Hendricks HT, Heeren AH, Vos PE. Dysautonomia after severe traumatic brain injury. Eur J Neurol. 2010;17(9):1172-1177.
Lv LQ, Hou LJ, Yu MK, et al. Risk factors related to dysautonomia after severe traumatic brain injury. J Trauma. 2011;71(3):538-542.
Perkes I, Baguley IJ, Nott MT, et al. A review of paroxysmal sympathetic hyperactivity after acquired brain injury. Ann Neurol. 2010;68(2):126-135.
Kirk KA, Shoykhet M, Jeong JH, et al. Dysautonomia after pediatric brain injury. Dev Med Child Neurol. 2012;54(8):759-764.
Samuel S, Lee M, Brown RJ, et al. Incidence of paroxysmal sympathetic hyperactivity following traumatic brain injury using assessment tools. Brain Inj. 2018;32(9):1115-1121.

Conflicts of Interest: None declared Funding: None Word Count: 4,247

Wednesday, September 17, 2025